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Introduction
Renal insufficiency is a common co-morbidity amongst patients with chronic heart failure (HF). It is associated with a worse prognosis and complicates therapeutic management.
Indeed renal impairment, independently of left ventricular ejection fraction (LVEF), is associated with neurohormonal activation and worse fatal and non-fatal outcomes in patients with both ischemic and non-ischemic HF 1,2 .
In clinical trials the relative benefit of several treatments is similar in patients with and without renal dysfunction. As a result, these treatments provide a large absolute benefit in patients with heart failure and renal insufficiency. This has been shown for ACE inhibitors 3 , digoxin 4 and the combination of hydralazine and isosorbide dinitrate 5 . In clinical practice, however, HF patients with renal insufficiency are less likely to receive efficacious therapies than patients with normal or near normal renal function 6,7 . The explanation for this is uncertain, but may be due to a real or perceived increased risk of treatment-related adverse effects in patients with renal impairment. There is limited evidence about the efficacy and tolerability of beta-blockers in patients with heart failure and renal dysfunction, originally arising from observational studies 7, 8, 9 , and more convincingly from two recent post hoc analyses of randomized clinical trials addressing these questions 10, 11 . Bisoprolol was the first beta-blocker to show beneficial effects on outcomes in patients with HF and left ventricular systolic dysfunction taking part in the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II) 12 . A report from the CIBIS-II 13 failed to answer thoroughly whether the treatment effect in heart failure of this selective β 1 antagonist with dual renal and hepatic routes of excretion varies by renal function. In our study we sought to expand and extend that analysis adjusting for potential confounders and taking in consideration the non linear relationship between renal function and outcomes in the assessment of treatment by renal function interaction.
Methods

Source population
The design, baseline characteristics of the participants in and the principal findings of CIBIS-II have been published elsewhere 12, 14 . In brief, CIBIS-II was a double-blind, randomized comparison of bisoprolol and placebo in 2647 ambulatory patients with New York Heart Association (NYHA) class III and IV HF and a left-ventricular ejection fraction of 35% or less. Patients were treated with a diuretic and an ACE-inhibitor (other vasodilators were allowed in the case of ACE-inhibitor intolerance) for at least two weeks before randomization. Eligible patients were commenced on bisoprolol 1.25 mg or placebo once daily, and the dose increased progressively to 2.5 mg, 3.75 mg, 5.0 mg, 7.5 mg and 10.0 mg according to tolerance. The trial was stopped prematurely, after a mean follow-up of 1.3 years, as β-blocker treatment led to a highly significant reduction in the primary endpoint of all-cause mortality, with a bisoprolol:placebo hazard ratio (and 95% confidence intervals) of 0.66 (0.54, 0.81), p<0.0001.
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Outcomes evaluated
In addition to the original study primary endpoint of all-cause mortality, we examined the effect of bisoprolol on the post hoc composite outcome of all-cause mortality or heart failure hospitalization, a commonly used endpoint in HF trials. We also evaluated the effect of bisoprolol on heart failure hospitalization alone. To evaluate tolerability and safety, we evaluated permanent premature treatment withdrawals (a secondary endpoint in the original study) and the post hoc composite outcome of all-cause mortality or all-cause hospitalization.
All medical events, including treatment withdrawals, were blindly reviewed and classified by members of an independent Critical Event Committee according to standardized definitions.
Statistical Analysis
Continuous variables are expressed as medians (with interquartile ranges) and categorical variables as counts and percentages. To assess differences in baseline characteristics among eGFR BSA categories we used the Kruskal-Wallis test for continuous variables and the χ 2 test for categorical variables. Kaplan-Meier analyses, stratified according to the eGFR BSA , for death from any cause and for all the other end points were determined and presented as event curves, compared by means of log-rank test. Cox proportional hazard models were used to compare each clinical outcome according to treatment intervention across eGFR BSA groups.
Multivariable analysis adjusted for age (years), sex, presence of diabetes mellitus, HF etiology (ischemic, idiopathic, others), baseline systolic blood pressure and ejection fraction.
The proportional hazards assumption was checked using scaled Schoenfeld residuals. To ascertain potential heterogeneity of the effect of bisoprolol across the entire spectrum of renal function, evidence of treatment by eGFR BSA categories interaction was investigated.
Analyses were conducted modeling eGFR BSA as a categorical and linear continuous variable.
To explore the nonlinear relationship between renal function and event free survival, we also modeled eGFR BSA as a restricted cubic spline.
All p values were 2 sided, and p < 0.05 was used to determine statistical significance.
Analyses were all based on intention-to-treat and were performed with STATA, version 10.1 (StataCorp LP, College Station, TX, USA).
Results
Baseline characteristics
A baseline eGFR BSA could be calculated for 2622 participants (99.1% of CIBIS-II patients).
The 25 subjects without a baseline eGFR BSA did not differ significantly in terms of demographic/clinical characteristics, treatment received and major outcomes from the population analyzed (data not shown).
The median eGFR BSA was 64.5 ml/min per 1.73 m 2 (IQR 49.9, 81.5). 863 (32.9%) patients had an eGFR BSA of at least 75 ml/min per 1.73 m 2 , 640 (24.4%) had an eGFR BSA of 60 to 74.9 ml/min per 1.73 m 2 , 669 (25.5%) had an eGFR BSA of 45 to 59.9 ml/min per 1.73 m 2 and 10 lowest and highest eGFR BSA category was 52 ml per minute per 1.73 m 2 and the difference in creatinine was 49 μmol/L (0.6 mg/dL).
Baseline demographic and clinical characteristics for patients in the four eGFR BSA categories are shown in Table 1 . Lower eGFR BSA was associated with older age, female sex, higher frequency of co-morbidities (hypertension, diabetes, coronary artery disease, peripheral and cerebrovascular disease) and ischemic etiology. There was no significant difference in the severity of HF (expressed as NYHA class), and, although statistically significant, the difference in ejection fraction (2%) between eGFR BSA groups was small. There was no difference in the allocation of randomized treatment across eGFR categories.
Among each eGFR BSA group no difference was found in the concomitant treatment with diuretic, ACE inhibitors, digoxin and antiplatelet agents whereas patients with lower eGFR BSA more often received amiodarone and anticoagulants.
Outcomes
All cause mortality
Death occurred in 379 patients during follow up. Figure 1 shows all-cause mortality for each eGFR BSA category. Reduced eGFR BSA at baseline was associated with higher mortality. Treating eGFR BSA as a linear continuous variable there was a 13% adjusted risk accrual for each 10-unit decrease in baseline renal function (p for eGFR BSA : treatment interaction = 0.85). The non-significant interaction between eGFR BSA transformed as a restricted cubic spline and treatment with bisoprolol and its effect on all-cause mortality is represented graphically in figure 2a.
All cause mortality or heart failure hospitalization
The risk of the composite outcome of all-cause mortality or heart failure hospitalization was also associated with renal impairment (figure 3). When compared with patients with normal or near normal renal function (≥ 75 ml/min per 1.73 m 2 ) patients with eGFR BSA < 45, between 45 and 59.9, between 60 and 74.9 ml/min per 1.73 m 2 had 2.5, 1.5 and 1.3 fold higher adjusted risks respectively. After multivariable adjustment, the effect of bisoprolol on the composite outcome was consistent across renal function groups (table 2) and was not influenced by baseline renal function (p for interaction = 0.66).
Modeling eGFR BSA as a linear continuous variable the adjusted risk accrual for each 10-unit decrease in renal function was 14% (p for interaction = 0.62). The graphical representation of interaction between bisoprolol and eGFR BSA transformed as a restricted cubic spline, for the composite endpoint is presented in figure 2b .
Heart failure hospitalization
Overall, 386 (14.7%) patients were hospitalized for worsening symptoms of heart failure during follow up. Patients in the lowest eGFR BSA category had a 2.9 fold higher adjusted risk of being hospitalized for worsening heart failure compared with subjects with eGFR BSA ≥ 75 ml/min per 1.73 m 2 whereas the risk of hospital admission was 1.8 fold and 1.3 fold higher for patients with an eGFR BSA of 45 to 59.9 and 60 to 74.9 ml/min per 1.73 m 2 respectively.
The adjusted bisoprolol:placebo hazard ratios for each eGFR BSA category are shown in table 2. The hazard ratio appeared to fall further as eGFR BSA increased into the near normal range, an impression reinforced by the graphical representation of interaction between bisoprolol and eGFR BSA transformed as a restricted cubic spline (figure 2c). However, the test for interaction was not statistically significant whether eGFR BSA was tested as a categorical (p=0.71) or a continuous (p=0.47) variable.
Tolerability and safety
During the entire duration of follow up the average daily dose of both bisoprolol and placebo was significantly lower for patients with baseline renal impairment (table 1) . Moreover the dose of bisoprolol was significantly lower than the dose of placebo across all the eGFR BSA categories. Nonetheless, after 3 months of follow up there was a trend towards a greater reduction in heart rate in patients in the lowest eGFR BSA category amongst those allocated to bisoprolol, compared with placebo (p for treatment-eGFR BSA interaction = 0.14) [table 3 ].
Similarly, there was trend for more of a reduction of diastolic blood pressure with bisoprolol, compared with placebo, in the lowest eGFR BSA category (p for treatment:eGFR BSA interaction = 0.18). The greatest fall in systolic blood pressure between baseline and 3 months was in patients with the worst baseline renal function but there was no betweentreatment difference in this change (treatment-eGFR BSA interaction p value = 0.40).
In patients with a baseline eGFR BSA < 45 ml/min per 1.73 m 2 there was a substantially higher rate of permanent discontinuation of bisoprolol than placebo (HR 1.54, CI 95% 1.01 to 2.33), as shown in figure 4 and table 2. Conversely, in those with baseline eGFR BSA ≥ 75 ml/min per 1.73 m 2 , the risk of drug discontinuation was lower for patients allocated to bisoprolol than among those allocated to placebo (HR 0.54, CI 95% 0.35 to 0.85). The relationship between baseline eGFR BSA on the risk of drug discontinuation (transformed as a restricted cubic spline) is illustrated further in figure 2d .
The effect of bisoprolol on the outcome of our post hoc global safety outcome of all-cause mortality or all-cause hospitalization was consistent across each eGFR BSA category (table 2) and unmodified by baseline renal function (p for interaction = 0.81). No significant interaction was observed when eGFR BSA was modeled as a linear continuous variable (p for interaction = 0.77).
Discussion
The main finding from the present analysis of CIBIS-II was the consistency of clinical benefit derived from bisoprolol across the entire spectrum of renal function as quantified using the body surface area adjusted Cockcroft and Gault formula. The role of renal insufficiency as a predictor of negative outcomes in patients with HF was also confirmed. As a consequence, the absolute benefit attributable to bisoprolol was higher for the primary and post hoc composite outcomes in patients with a reduced compared to a normal or near normal eGFR BSA . This benefit was realized despite patients with worse renal function achieving a lower dose of and having a higher rate of discontinuation of bisoprolol.
Renal function in heart failure
While renal insufficiency is a common and challenging co-morbidity in patients with HF in CIBIS-II had a less stringent renal exclusion criterion than many trials, allowing enrolment of patients with a creatinine of up to 3.4 mg/dL (300 μmol/L). As a result, more than 40% of patients in CIBIS-II had moderate to severe renal dysfunction, namely an eGFR BSA < 60 ml/min per 1.73 m 2 according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 18 .
Effects of bisoprolol according to renal function
Our analysis has shown that in stable patients with moderate to severe heart failure caused by suggested that the efficacy of nebivolol was not reduced in elderly HF patients with mild or moderate renal impairment. Similar to our findings, a non significant interaction between baseline renal function and the effect of nebivolol was found 11 . Like metoprolol, metabolism and elimination of nebivolol is almost entirely hepatic with a minimal amount of the drug excreted unchanged in the urine. Nevertheless, some important differences between SENIORS and CIBIS-II design must be considered. In SENIORS patients were excluded if their baseline serum creatinine was higher than 2.8 mg/dL (250 μmol/L). Moreover, the enrollment of patients with mildly symptomatic HF (more than 50% were in NYHA class I-II) and with an ejection fraction >35% (more than one third of the entire population) was permitted.
We found a trend towards a greater reduction in heart rate and diastolic blood pressure with bisoprolol (compared to placebo) in patients with the most reduced renal function. This might be explained by greater sympathetic over-activity in patients with the worst renal function (although baseline heart rate did not vary notably across eGFR BSA categories, similar to what was reported in MERIT-HF) or could be due to bisoprolol accumulation in those patients. In keeping with this latter hypothesis was the higher rate of permanent treatment withdrawals observed in the lowest eGFR BSA category amongst patients allocated to bisoprolol. Of note, the rate of discontinuation of metoprolol (compared to placebo), for adverse events, was not increased in the lowest eGFR category in MERIT-HF, although overall discontinuation rates were not reported. It is possible that accumulation of bisoprolol could have led to a decline in renal function and sodium and water retention. Although this has been demonstrated to occur acutely in response to a single large intravenous dose of bisoprolol in patients with hypertension 30 , we do not know if this occurs chronically in patients with heart failure and serial measurement of renal function was not performed in CIBIS-II. It needs to be reiterated, however, that a larger absolute benefit was obtained with bisoprolol in patients in the lowest (compared to the highest) eGFR BSA category in CIBIS-II.
The only other relevant study we know of is a small placebo-controlled trial in which the effects of carvedilol on mortality and morbidity were investigated in 114 patients with endstage renal disease and associated dilated cardiomyopathy receiving regular hemodialysis.
After one year of carvedilol therapy left ventricular function improved compared to placebo.
At two years follow up, the number of deaths in the carvedilol group was 30 (51.7%) compared to 41 (73.2%) in the placebo group (p < 0.01). Moreover, significantly fewer patients receiving carvedilol were admitted to hospital 36 .Unfortunately, because of the design of this study we cannot compare dose of treatment achieved, hemodynamic effects and discontinuation rates according to the degree of renal dysfunction at baseline.
Our study has a number of strengths. To the best of our knowledge no previous report has investigated the interaction between renal dysfunction and the effect of bisoprolol on mortality and heart failure hospitalization in patients with HF in advanced NYHA class.
Moreover, we also investigated the tolerability and safety of bisoprolol in this clinical setting.
In CIBIS-II, given the high serum creatinine threshold allowed for enrolment, almost half of the entire population presented moderate to severe renal impairment. A number of limitations should also be noted. Renal function was estimated and not measured by means of reference method (e.g. iothalamate clearance). We used the Cockcroft-Gault formula to estimate glomerular filtration rate as done in several previous studies 1,2,37 . Furthermore, we normalized for body surface area to increase the accuracy of the original equation 19, 38 . We found that 43% of patients had an eGFR < 60 ml/min whilst in a previous analysis of CIBIS-2 this proportion was 32% 13 . This discrepancy is due to the different equations used and we believe that our analysis better represents the true renal function in this cohort. Measurement 
Clinical implications
Among patients with HF due to left ventricular systolic dysfunction bisoprolol was effective, regardless baseline renal impairment. Therefore, the value of beta-blockers should be reinforced amongst those with HF and CKD, especially as the absolute gains may be higher. 
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